Volume 20, Issue 3 (Iranian South Medical Journal 2017)
Iran South Med J 2017, 20(3): 278-286 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Esmaili A, Dehghani Zahedani M, Nili F. P63 marker Expression in Usual Skin Cancers Compared With Non Tumoral Skin Lesions. Iran South Med J 2017; 20 (3) :278-286
URL: http://ismj.bpums.ac.ir/article-1-879-en.html
URL: http://ismj.bpums.ac.ir/article-1-879-en.html
1- Department of Pathology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran , hamidsporteduction@gmail.com
2- Department of Pathology, School of Medicine, Hormozgan University of Medical Sciences, Hormozgan, Iran
3- Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Pathology, School of Medicine, Hormozgan University of Medical Sciences, Hormozgan, Iran
3- Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (4863 Views)
Background: Non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma are the most common malignant diseases in human. The aim of this study was to determine the expression of the P63 marker in common skin cancers and non-tumoral skin lesions and compared the difference between them.
Materials and Methods: In this cross-sectional study, sampling was performed from the archive of sample blocks from patients admitted in Shahid Mohammadi Hospital during 2010-2011. Sixty samples (including 30 samples of non-tumoral skin lesions and 30 samples including basal cell carcinoma and squamous cell carcinoma) were studied. The evaluation of p63 gene expression was performed using immunohistochemistry method. Student’s T-test and Chi-square test were used for analysis of the data.
Results: P63 gene were expressed in 4 cases (13.33 %) of non_tumoral lesions and all tumoral lesions (100%). In tumoral lesions, 5 cases (16.66 %) showed 1+ severity expression, 11 cases (36.66%) 2+severity expression and 14 cases (46.66 %) 3+severity expression. All 4 non-tumoral lesions showed 1+severity expression of P63gene.
Conclusion: The results of this study indicated that the frequency and severity of gene expression of P63 could be used for differentiation between basal cell carcinoma and squamous cell carcinoma as well as non-tumoral skin lesions.
Type of Study: Original |
Subject:
Dermatology
Received: 2014/10/1 | Accepted: 2016/10/16 | Published: 2017/07/5
Received: 2014/10/1 | Accepted: 2016/10/16 | Published: 2017/07/5
References
1. Hao ZF, Ao JH, Zhang J, et al. ATF3 activates Stat3 phosphorylation through inhibition of p53 expression in skin cancer cells. Asian Pac J Cancer Prev 2013; 14(12): 7439-44. [DOI:10.7314/APJCP.2013.14.12.7439]
2. Suh KY, Lacouture M, Gerami P. p63 in Primary Cutaneous Carcinosarcoma. Am J Dermatopathol 2007; 29(4): 374-7. [DOI:10.1097/DAD.0b013e31812f52bd]
3. Pothiawala S, Qureshi AA, Li Y, et al. Obesity and the incidence of skin cancer in US Caucasians. Cancer Causes control 2012; 23(5): 717-26. [DOI:10.1007/s10552-012-9941-x]
4. Jiang DK, Wang WZ, Ren WH, et al. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol 2011; 131(1): 220-8. [DOI:10.1038/jid.2010.270]
5. Rangel LP, Costa DC2, Vieira TC2, et al. The aggregation of mutant p53 produces prion-like properties in cancer. Prion 2014; 8(1): 75-84. [DOI:10.4161/pri.27776]
6. Li DH, Zhang LQ, He FC. Advances on mutant p53 research. Yi Chuan 2008; 30(6): 697-703. [DOI:10.3724/SP.J.1005.2008.00697]
7. Strano S, Dell'Orso S, Di Agostino S, et al. Mutant p53: an oncogenic transcription factor. Oncogene 2007; 26(15): 2212-9. [DOI:10.1038/sj.onc.1210296]
8. Yang X, Yang B, Liu Y, et al. The association between TP53 Arg72pro polymorphism and non-melanoma skin cancer risk: a meta-analysis including 7, 107 subjects. Indian J Dermatol 2013; 58(3): 175-80. [DOI:10.4103/0019-5154.110823]
9. Amelio I, Grespi F, Annicchiarico-Petruzzelli M, et al. p63 the guardian of human reproduction. Cell Cycle 2012; 11(24): 4545-51. [DOI:10.4161/cc.22819]
10. McDade SS, Henry AE, Pivato GP, et al. Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation. Nucleic Acids Res 2012; 40(15): 7190-206. [DOI:10.1093/nar/gks389]
11. Li Q, Sambandam SA, Lu HJ, et al. 14-3-3σ and p63 play opposing roles in epidermal tumorigenesis. Carcinogenesis 2011; 32(12): 1782-8. [DOI:10.1093/carcin/bgr207]
12. Cordani N, Pozzi S, Martynova E, et al. Mutant p53 subverts p63 control over KLF4 expression in keratinocytes. Oncogene 2011; 30(8): 922-32. [DOI:10.1038/onc.2010.474]
13. McDade SS, McCance DJ. The role of p63 in epidermal morphogenesis and neoplasia. Biochem Soc Trans 2010; 38(Pt 1): 223-8. [DOI:10.1042/BST0380223]
14. Flores ER. The roles of p63 in cancer. Cell Cycle 2007; 6(3): 300-4. [DOI:10.4161/cc.6.3.3793]
15. Brunner HG, Hamel BCJ, Bokhoven H. P63 gene mutations and human developmental syndromes. Am J Med Genet A 2002; 112(3): 284-90. [DOI:10.1002/ajmg.10778]
16. Kanitakis J, Chouvet B. Expression of p63 in cutaneous metastases. Am J Clin Pathol 2007; 128(5): 753-8. [DOI:10.1309/BD3K8U7KD969Y07U]
17. Sakiz D, Turkmenoglu TT, Kabukcuoglu F. The expression of p63 and p53in kerathoacanthoma and intraepidermal and invasive neoplasms of skin. Pathol Res Pract 2009; 205(9): 589-94 [DOI:10.1016/j.prp.2009.01.010]
18. McDade SS, McCance DJ. The role of p63 in epidermal morphogenesis and neoplasia. Biochem Soc Trans 2010; 38(Pt 1): 223-8. [DOI:10.1042/BST0380223]
19. Tan KB, Tan SH, Aw DC, et al. Simulators of squamous cell carcinoma of the skin: Diagnostic challenges on small biopsies and clinicopathological correlation. J Skin Cancer 2013; 2013: 752864. [DOI:10.1155/2013/752864]
20. Nakamura Y, Ishitsuka Y, Ohara K, et al. Basal cell carcinoma on the dorsum of the foot with inguinal and pelvic lymph nodes metastases. Int J Dermatol 2012; 51(9): 1068-73. [DOI:10.1111/j.1365-4632.2011.05363.x]
21. Christian MM, Murphy CM, Wagner RF Jr. Metastatic basal cell carcinoma presenting as unilateral lymphedema. Dermatol Surg 1998; 24(10): 1151-3. [DOI:10.1111/j.1524-4725.1998.tb04089.x]
22. Berlin JM, Warner MR, Bailin PL. Metastatic basal cell carcinoma presenting as unilateral axillary lymphadenopathy: report of a case and review of the literature. Dermatol Surg 2002; 28(11): 1082-4. [DOI:10.1097/00042728-200211000-00022]
23. Moore BA, Weber RS, Prieto V, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope 2005; 115(9): 1561-7. [DOI:10.1097/01.mlg.0000173202.56739.9f]
24. Fagan JJ, Collins B, Barnes L, et al. Perineural invasion in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124(6): 637-40. [DOI:10.1001/archotol.124.6.637]
25. Kurtz KA, Hoffman HT, Zimmerman MB, et al. Perineural and vascular invasion in oral cavity squamous carcinoma: increased incidence on re-review of slides and by using immunohistochemical enhancement. Arch Pathol Lab Med 2005; 129(3): 354-9.
26. Geist DE, Garcia-Moliner M, Fitzek MM, et al. Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg 2008; 34(12): 1642-51. [DOI:10.1111/j.1524-4725.2008.34341.x]
27. Bechert CJ, Stern JB. Basal cell carcinoma with perineural invasion: reexcision perineural invasion. J Cutan Pathol 2010; 37(3): 376-9. [DOI:10.1111/j.1600-0560.2009.01331.x]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
